), a leader in mechanical circulation support devices, recently
revealed that it has received approval from the Food and Drug
Administration (FDA) to sell the HeartMate II Pocket Controller
meant for use with the HeartMate II LVAD System.
The Pocket Controller is smaller than earlier versions of left
ventricular assist device (LVAD) system controllers. It comes
with a friendly interface for the user. The controller fits into
the front pocket and is intended to facilitate the busy routine
of patients using HeartMate II LVADs.
Thoratec will start providing training at domestic centers for
the Pocket Controller in the week of May 20, 2013. Subsequently,
the Pocket Controller may be procured by
Thoratec enjoys a first-mover advantage in the market it
serves. With HeartMate II, Thoratec enjoys a monopoly in the U.S.
market since it has developed the only device of its kind for the
destination therapy indication (for heart failure patients who
are not eligible for heart transplant).
However, its dominance in the bridge-to-transplant (BTT)
indication has ended following the FDA approval of
) Ventricular Assist System in Nov 2012. Competition with
HeartWare has led to loss of market share and revenue shortfall
Despite limited visibility and periodic setbacks, Thoratec has
successfully expanded its sales on the back of its HeartMate II
product line. The company continues to do well in overseas
markets although the base is small. It received reimbursement
approval in Japan on Apr 1, 2013, which enables it to
commercialize the HeartMate II as a BTT for victims of advanced
heart failure. Thoratec commercialized the Pocket Controller in
Europe in Mar 2013.
The stock carries a Zacks Rank #4 (Sell). We are more
Becton, Dickinson and Company
) which carries a Zacks Rank #2 (Buy) and is expected to do well.
) carries a Zacks Rank #1 (Strong Buy) and warrants a look.
BECTON DICKINSO (BDX): Free Stock Analysis
CONCEPTUS INC (CPTS): Free Stock Analysis
HEARTWARE INTL (HTWR): Free Stock Analysis
THORATEC CORP (THOR): Free Stock Analysis
To read this article on Zacks.com click here.